about
Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal AntibodyA Modular Vaccine Development Platform Based on Sortase-Mediated Site-Specific Tagging of Antigens onto Virus-Like ParticlesPhylogenetic analysis of the major causative agents of hand, foot and mouth disease in Suzhou City, Jiangsu province, China, in 2012-2013.Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps.Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral EntryAn Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions.Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms.The molecule of DC-SIGN captures enterovirus 71 and confers dendritic cell-mediated viral trans-infection.Towards broadly protective polyvalent vaccines against hand, foot and mouth disease.Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral CapsidsA bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice.Antibodies to P-selectin glycoprotein ligand-1 block dendritic cell-mediated enterovirus 71 transmission and prevent virus-induced cells death.Characterization of enterovirus 71 capsids using subunit protein-specific polyclonal antibodies.Fighting Ebola with ZMapp: spotlight on plant-made antibody.Transcutaneous immunization via rapidly dissolvable microneedles protects against hand-foot-and-mouth disease caused by enterovirus 71.Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge.Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections.Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice.Coxsackievirus A16-like particles produced in Pichia pastoris elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice.High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice.Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71.A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.Single-particle tracking of hepatitis B virus-like vesicle entry into cells.Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins.Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71.
P50
Q28550496-F4E7E86D-B2DA-4CD1-A00E-03DBE546C20CQ28834387-36BA8973-F4AF-41E1-921C-DE26AA5AF503Q30375266-38A47B76-0EBE-4ED2-BC69-0294DAA033AFQ34603692-C5B04C70-F236-444B-97C1-065611336A90Q36281127-FEFA34A0-0B8B-45BE-BAE4-5BA10DEBCFC5Q37252982-D055FC8F-B3B8-41E2-9A05-F0C978365023Q37415463-90626C24-416E-42AA-AD6C-6567EFD920B6Q37547757-043AC2BF-A4DC-46E6-A249-F9FCEE72E5F6Q37716692-E3733ED0-3EB1-4545-A49D-07E263B744C2Q38275640-210CE821-4560-45D3-89DF-DCF74338130AQ38763206-FD52885A-F214-4F3D-9B06-A36F6D4C0E36Q38831138-E6631BA1-5534-40CF-B6A7-FA393639EE7FQ38833043-18D4C943-E6F4-48AE-AAE3-F94534CE2AABQ39263620-50D3779C-EC6F-4F4F-99C7-698003A228F0Q40191158-991DA32C-D887-4AB3-BECF-82F1F278DFB6Q40465779-A69015EC-0CE5-4E98-A146-C81B618266AEQ40562925-C6976FAB-5237-4FE3-BCF1-E81A6EC91C0CQ40638141-F62C7DC2-9775-481D-A10B-BDEB3FA7966BQ40694817-095430B7-891B-48A7-9985-540FACB09668Q40782188-47FFEE0B-11E2-4392-B78C-3B26BAA716FFQ41373115-30663E17-9FBB-4D39-9E10-4A951E00666EQ41462898-BA636BDD-6A7B-4479-9015-15AB0F28AFC0Q42222745-9099F783-241B-449F-B2B8-FC72647A4708Q45367732-EFC9CAB4-D870-4155-ABA3-E0943CD31565Q46973953-8C020824-044C-4948-8AB4-17A1EE70B853Q47409667-FE81DFA0-B7DB-45A7-8156-F9F951F3A430
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Zhong Huang
@ast
Zhong Huang
@en
Zhong Huang
@es
Zhong Huang
@nl
Zhong Huang
@sl
type
label
Zhong Huang
@ast
Zhong Huang
@en
Zhong Huang
@es
Zhong Huang
@nl
Zhong Huang
@sl
prefLabel
Zhong Huang
@ast
Zhong Huang
@en
Zhong Huang
@es
Zhong Huang
@nl
Zhong Huang
@sl
P108
P106
P1153
55494523100
P31
P496
0000-0002-2161-1359
P569
2000-01-01T00:00:00Z